VaxForm is awarded a Phase I SBIR grant from the National Science Foundation (NSF) to support the development of their oral COVID-19 vaccine candidate.
VaxForm is awarded $300,000 from the PA Department of Community and Economic Development to support the development of their oral COVID-19 vaccine candidate.
VaxForm is awarded a Phase I SBIR grant from the National Science Foundation (NSF) to further develop their oral vaccine delivery platform. The project is entitled: "Incorporation of a new adjuvant system to produce a thermally stable, orally administered Diphtheria Tetanus Pertussis vaccine."
VaxForm publishes their latest results from the pre-clinical development of their recombinant fusion protein vaccine targeting Streptococcus Pyogenes bacteria in AAPS Journal. The vaccine successfully induced neutralizing antibodies in mice and displayed robust stability.
VaxForm publishes the results of the non-clinical safety studies of their vaccine candidate for Streptococcus Pyogenes. Rabbits were administered the maximum anticipated dose of the vaccine and exhibited no significant adverse reaction events. This is a great milestone achievement towards the initiation of first-in-human clinical trial of the vaccine.